Pfizer (Australia) LEUCOVORIN CALCIUM folinic acid (as calcium folinate) 100mg/10mL injection USP ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer (australia) leucovorin calcium folinic acid (as calcium folinate) 100mg/10ml injection usp ampoule

pfizer australia pty ltd - calcium folinate, quantity: 10.8 mg/ml (equivalent: folinic acid, qty 10 mg/ml) - injection, solution - excipient ingredients: hydrochloric acid; sodium hydroxide; sodium chloride; water for injections - leucovorin calcium injection usp is indicated following high dose methotrexate therapy to reduce toxicity (leucovorin rescue). it is also indicated after inadvertent overdosage with methotrexate and in impaired methotrexate elimination.

Pfizer (Australia) LEUCOVORIN CALCIUM folinic acid (as calcium folinate) 50mg/5mL injection USP ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer (australia) leucovorin calcium folinic acid (as calcium folinate) 50mg/5ml injection usp ampoule

pfizer australia pty ltd - calcium folinate, quantity: 10.8 mg/ml (equivalent: folinic acid, qty 10 mg/ml) - injection, solution - excipient ingredients: water for injections; sodium hydroxide; sodium chloride; hydrochloric acid - leucovorin calcium injection usp is indicated following high dose methotrexate therapy to reduce toxicity (leucovorin rescue). it is also indicated after inadvertent overdosage with methotrexate and in impaired methotrexate elimination.

Pfizer (Australia) METHOTREXATE 500mg/20mL injection BP vial Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer (australia) methotrexate 500mg/20ml injection bp vial

pfizer australia pty ltd - methotrexate, quantity: 500 mg - injection, solution - excipient ingredients: water for injections; sodium chloride; hydrochloric acid; sodium hydroxide - antineoplastic chemotherapy - treatment of breast cancer, gestational choriocarcinoma and in patients with chorioadenoma destruens and hydatidiform mole. palliation of acute and subacute lymphocytic and meningeal leukaemia. greatest effect has been observed in palliation of acute lymphoblastic (stem cell) leukaemia. in combination with corticosteroids, methotrexate may be used for induction of remission. the drug is now most commonly used for the maintenance of induced remissions. methotrexate is also effective in the treatment of the advanced stages (iii and iv, peters staging system) of lymphosarcoma, particularly in children and in advanced cases of mycosis fungoides. high dose therapy - the use of very high doses is made possible by vials for injection containing 500 mg and 1000 mg (see precautions). diseases treated with these doses administered in the form of single-drug or combination therapy, include osteogenic sarcoma, acute leukaemia, bronchogenic carcinoma and epidermoid carcinoma of the head and n

Pfizer (Australia) DAUNORUBICIN (as hydrochloride) 20mg/10mL injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer (australia) daunorubicin (as hydrochloride) 20mg/10ml injection vial

pfizer australia pty ltd - daunorubicin, quantity: 20 mg - injection, solution - excipient ingredients: sodium chloride; water for injections; sodium hydroxide; hydrochloric acid - indications as at 22 november 2004 : daunorubicin injection is indicated for the treatment of the following: acute lymphocytic (lymphoblastic) leukaemia: daunorubicin is usually reserved for use in cases shown to be resistant to other drugs. however, combined treatment with daunorubicin, vincristine and a steroid has been used in the early stages of this disease. acute myeloblastic leukaemia: daunorubicin has been used in all stages, alone or in combination with other cytotoxic agents (e.g. cytarabine). disseminated solid tumours: daunorubicin has been investigated for use in these tumours and found to be effective in some cases of disseminated neuroblastoma and rhabdomyosarcoma.

Pfizer (Australia) GLUCOSE INTRAVENOUS INFUSION BP 5% glucose (as monohydrate) 5g/100 mL injection for infusion vial Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer (australia) glucose intravenous infusion bp 5% glucose (as monohydrate) 5g/100 ml injection for infusion vial

pfizer australia pty ltd - glucose monohydrate, quantity: 54.99 mg/ml (equivalent: glucose, qty 50 mg/ml) - injection, intravenous infusion - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - indications as at 31 july 2000: for fluid and carbohydrate depletion wherever a non-electrolyte fluid is required. in the treatment of hypoglycaemia. in the treatment of acute diarrhoeal disease. as a vehicle for the administration of other medications.

PARACETAMOL IV PFIZER Australia - English - Department of Health (Therapeutic Goods Administration)

paracetamol iv pfizer

pfizer australia pty ltd - paracetamol, quantity: 1 g - injection, solution - excipient ingredients: glucose monohydrate; sodium citrate dihydrate; water for injections; glacial acetic acid; hydrochloric acid; sodium acetate trihydrate; sodium hydroxide - for the relief of mild to moderate pain and the reduction of fever where an intravenous route of administration is considered clinically necessary.

PARACETAMOL IV PFIZER Australia - English - Department of Health (Therapeutic Goods Administration)

paracetamol iv pfizer

pfizer australia pty ltd - paracetamol, quantity: 500 mg - injection, solution - excipient ingredients: hydrochloric acid; sodium citrate dihydrate; sodium acetate trihydrate; glucose monohydrate; sodium hydroxide; glacial acetic acid; water for injections - for the relief of mild to moderate pain and the reduction of fever where an intravenous route of administration is considered clinically necessary.